All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000726-78 | A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women with Excessive Facial Hair | 2005-07-04 | due-trials |
| Reported results | 2004-000733-12 | A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 give... | 2013-09-20 | due-trials |
| Reported results | 2004-000734-36 | A phase III, randomized, multi-center, open-label, 12 to 14 months extension study to evaluate the safety and tolerability of SPD476 (mesalazine) give once daily vs. twice daily for the maintenance of... | 2006-03-13 | due-trials |
| Reported results | 2004-001608-11 | A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stag... | 2005-08-22 | due-trials |
| Reported results | 2004-002743-27 | An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy | 2008-01-31 | due-trials |
| Reported results | 2004-004058-20 | A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (≥ 65 years) patients with essential thrombocythae... | 2008-04-03 | due-trials |
| Reported results | 2004-004061-15 | A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients. | 2015-12-15 | due-trials |
| Reported results | 2004-004184-29 | A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day ... | 2009-10-05 | due-trials |
| Reported results | 2006-002052-15 | An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Four Dosing Schedules of Subcutaneous Dynepo in Adult Patients with Anaemia Associat... | 2008-09-30 | due-trials |
| Reported results Terminated | 2006-002833-19 | A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism) | 2006-11-03 | due-trials |
| Reported results | 2006-003364-64 | A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion from Standard Phosphate Binder Therapy to Fosrenol in Chronic Kidney Disease Stage 5 Patients on Haemodialysis. | 2008-07-30 | due-trials |
| Reported results | 2006-004959-38 | A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal di... | 2008-07-21 | due-trials |
| Exempt, with results | 2006-005341-11 | A single center, open-label, non-randomized, uncontrolled, multiple-dose, dose escalation study of the safety, pharmacokinetics and efficacy of Metazym (recombinant human arylsulfatase A or rhASA) for... | 2008-03-25 | not-yet-due |
| Reported results | 2006-006304-11 | A Multicenter Open-Label Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease Previously Treated with Imiglucerase | 2009-08-27 | due-trials |
| Reported results | 2007-000054-31 | An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease. | 2008-10-30 | due-trials |
| Reported results | 2007-002840-21 | A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared with Imiglucerase in Patients with Type I Gaucher ... | 2009-07-28 | due-trials |
| Reported results | 2007-004895-37 | A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of... | 2012-03-05 | due-trials |
| Reported results | 2007-004896-20 | A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of... | 2011-11-28 | due-trials |
| Reported results | 2007-005543-22 | A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease | 2012-07-05 | due-trials |
| Reported results | 2007-006044-22 | A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy | 2011-07-08 | due-trials |
| Reported results | 2007-006345-40 | A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and long-term safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of patient... | 2008-09-23 | due-trials |
| Reported results | 2007-007165-20 | A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of MLD patients with... | 2008-12-04 | due-trials |
| Reported results | 2007-007872-40 | Determination of the rhIGF-I/rhIGFBP-3 Dose; Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal SErum IGF-I Levels within Physiological Levels in Premature Infants,... | 2016-03-30 | due-trials |
| Reported results | 2008-000084-41 | A Multi-center, Open-Label Extension Study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) Treatment in Patients with Late Infantile Metachromatic Leukodystrophy (MLD) | 2010-10-22 | due-trials |
| Reported results | 2008-000679-90 | A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Ado... | 2011-03-16 | due-trials |
| Reported results | 2008-000720-10 | A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Atte... | 2011-10-26 | due-trials |
| Reported results | 2008-001965-27 | An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease | 2012-12-28 | due-trials |
| Reported results | 2009-011745-94 | A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents ag... | 2012-07-19 | due-trials |
| Reported results | 2009-015652-20 | A 12-week, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of prucalopride in subjects with chronic non-cancer pain suffering from opioid induced constipation | 2012-08-23 | due-trials |
| Reported results | 2009-015719-42 | A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipation | 2013-10-25 | due-trials |
| Exempt, with results | 2009-015984-15 | A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan-N-sulfatase (rhHNS) Intrathecal Administration via an Intrathecal Drug Delivery Device in Patien... | 2012-09-10 | not-yet-due |
| Reported results | 2009-015985-75 | An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients with Fabry Disease | 2013-07-24 | due-trials |
| Reported results | 2009-016531-35 | A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo controlled Study to Assess the Effect of Lanthanum Carbonate on intact FGF23 in Normo-phosphataemic Subjects with Stage ... | 2012-04-16 | due-trials |
| Reported results | 2009-017044-13 | A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term... | 2012-12-14 | due-trials |
| Reported results | 2009-018161-12 | A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolesc... | 2013-07-09 | due-trials |
| Reported results | 2010-018579-12 | A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children an... | 2013-06-24 | due-trials |
| Reported results | 2010-019645-25 | A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy... | 2013-01-08 | due-trials |
| Reported results | 2010-019887-35 | A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial | 2013-06-20 | due-trials |
| Exempt, with results | 2010-020048-36 | A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT administered in conjunction with intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cog... | 2012-10-29 | not-yet-due |
| Reported results | 2010-020951-30 | A Phase 3, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD) | 2014-10-17 | due-trials |
| Exempt, with results | 2010-021348-16 | An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients with Sanfilippo Syndrome Type A (MPS IIIA) | 2019-02-28 | not-yet-due |
| Reported results | 2010-021397-12 | An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux diseas... | 2012-05-29 | due-trials |
| Reported results | 2010-022402-40 | Trial consisting of an 8-week double-blind placebo-controlled part to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in paediatric subjects with functional constipation... | 2013-03-01 | due-trials |
| Reported results | 2010-024247-32 | A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO D... | 2014-07-25 | due-trials |
| Exempt, with results | 2011-000164-10 | A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis | 2013-06-27 | not-yet-due |
| Trial is partly outside EEC | 2011-000212-25 | An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Patient... | bad-data | |
| Reported results | 2011-000670-62 | A randomised, double-blind, placebo-controlled trial to evaluate the efficacy, quality of life, safety and tolerability of long-term treatment (24 weeks) with prucalopride in subjects aged ≥ 18 year... | 2012-12-19 | due-trials |
| Exempt, with results | 2011-002044-28 | A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy | 2017-01-20 | not-yet-due |
| Trial is outside EEC, and reported results | 2011-002221-21 | A Phase 3, Double-blind, Randomized, Multi-center, Placebo controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once daily Dosing with Extended-release Guanfacine H... | bad-data | |
| Reported results | 2011-003006-25 | Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatme... | 2013-12-10 | due-trials |
| Reported results | 2011-003018-17 | The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in... | 2013-12-23 | due-trials |
| Reported results Terminated | 2011-003019-47 | A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Resi... | 2014-03-27 | due-trials |
| Reported results | 2011-003615-28 | A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in t... | 2014-01-17 | due-trials |
| Reported results | 2011-003825-81 | A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Heredit... | 2018-03-12 | due-trials |
| Reported results | 2011-004388-62 | A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophage... | 2013-05-14 | due-trials |
| Reported results | 2011-004668-31 | A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participated in S... | 2015-09-15 | due-trials |
| Reported results | 2011-005452-34 | A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, in ... | 2014-05-14 | due-trials |
| Reported results Terminated | 2011-006322-25 | A PHASE 3, OPEN-LABEL, MILTICENTRE, EXTENSION SAFETY AND TOLERABILITY STUDY FOR TRANSFUSIONALLY IRON OVERLOADED CHILDRE, ADOLISCENTS AND ADULTS USING FBS0701 (SSP-004184) STUDIO CLINICO MULTICENTRI... | 2014-08-01 | due-trials |
| Reported results | 2012-000083-24 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, DOSERANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) WITH RECOM... | 2014-12-23 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-000171-17 | A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate us... | 2018-11-16 | bad-data |
| Reported results | 2012-001815-21 | A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalize... | 2013-10-02 | due-trials |
| Reported results | 2012-002031-28 | A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH ULCERATIVE COLITIS (TURANDOT II) | 2017-12-13 | due-trials |
| Reported results | 2012-002495-13 | An Open-label, Randomized, Crossover, Reader-blinded Study To Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility with Intraluminal Manometry in Subjects with Chronic... | 2013-11-27 | due-trials |
| Reported results | 2012-003309-91 | The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged ... | 2013-09-25 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-003310-14 | The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged ... | bad-data | |
| Reported results | 2012-003313-34 | A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder | 2014-10-28 | due-trials |
| Trial is outside EEC, and reported results | 2012-003427-38 | A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease | bad-data | |
| Exempt | 2012-003775-20 | An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy | not-yet-due | |
| Reported results | 2012-004457-88 | A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating ... | 2015-04-08 | due-trials |
| Reported results | 2012-005760-99 | A Phase 4, Randomized-withdrawal, Double-blind, Placebo controlled, Parallel-group Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic Ort... | 2013-11-11 | due-trials |
| Completed, but no date, and reported results | 2012-005761-12 | A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic Orthostatic Hypoten... | bad-data | |
| Reported results | 2013-000743-33 | A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in β-thalassemia Subjects Administe... | 2014-07-15 | due-trials |
| Reported results | 2013-001744-65 | A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Paediatric Subjects with Mild to Moderate Ulcerative Colitis, in both Acute ... | 2018-11-28 | due-trials |
| Reported results | 2013-002453-29 | A PHASE 3, MULTICENTER, RANDOMIZED, SINGLE-BLIND, DOSE-RANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PR... | 2017-05-04 | due-trials |
| Reported results | 2013-002885-38 | A Controlled,Randomized,Two-arm,Open-label,Assessor-blinded,Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and Ea... | 2017-09-28 | due-trials |
| Reported results | 2013-003450-24 | A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Ped... | 2016-06-01 | due-trials |
| Reported results | 2014-001213-12 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)... | 2015-08-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003556-31 | Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | 2021-09-28 | bad-data |
| Reported results | 2014-003960-20 | A Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Pedia... | 2019-03-07 | due-trials |
| Other | 2014-004143-13 | An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome an... | not-yet-due | |
| Ongoing | 2014-004804-31 | A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Ye... | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2014-005086-70 | A Multicenter Study to Monitor for the Potential Development of Renal Tumors in Subjects With Transfusional Iron Overload Who Were Previously Exposed to Deferitazole Studio multicentrico per monit... | bad-data | |
| Reported results Terminated | 2015-000726-11 | A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney tran... | 2019-05-31 | due-trials |
| Reported results Terminated | 2015-000906-20 | An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Alagille Syndrome (ALGS) or ... | 2015-07-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001578-17 | An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment with Velaglucerase alfa on Bone-related Pathology in Treatment-naïve Patients with Type 1 Gaucher Disease | 2020-11-30 | bad-data |
| Reported results | 2015-002478-19 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esteras... | 2017-07-24 | due-trials |
| Reported results | 2015-003943-20 | HELP Study™: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE) | 2017-04-13 | due-trials |
| Reported results | 2015-004725-13 | A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients wi... | 2020-08-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-004726-34 | A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (... | 2022-07-01 | bad-data |
| Reported results | 2015-005255-27 | HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) | 2019-10-31 | due-trials |
| Reported results | 2016-000203-82 | A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter In... | 2018-07-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000849-30 | A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome Who Completed TED-C14-006 Original PIP P/238/2010 | 2020-11-05 | bad-data |
| Reported results | 2016-000863-17 | A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003 Original PIP P/238/2010 | 2020-07-14 | due-trials |
| Reported results Terminated | 2016-002439-14 | A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine an... | 2019-05-16 | due-trials |
| Reported results | 2016-003361-25 | A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in th... | 2018-10-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000284-32 | A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant H... | 2022-05-19 | bad-data |
| Reported results | 2017-000572-28 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302) | 2020-10-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000573-37 | A Phase 3 Randomized, Double-blind, Placebo controlled, Parallel group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303) | 2021-07-01 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000574-11 | A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis (AIDA) Estudio de fase 3, de extensión de seguridad a largo plazo de SHP647 en sujetos co... | 2023-12-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000575-88 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305) | 2020-10-08 | bad-data |
| Reported results | 2017-000576-29 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306) | 2020-08-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000599-27 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 301) | 2020-10-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000617-23 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) | 2021-09-13 | bad-data |
| Reported results | 2017-003067-36 | An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects with Hypoparathyroidism. | 2020-04-14 | due-trials |
| Reported results | 2017-003606-40 | A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age with Short Bowel Syndrome Who are Dependent on Parenteral Support Origina... | 2020-09-24 | due-trials |
| Ongoing | 2018-000821-29 | A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label ... | not-yet-due | |
| Ongoing | 2018-001393-16 | A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compa... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2018-002093-42 | SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE... | 2021-10-30 | bad-data |
| Other | 2018-003291-12 | A Global, Multicenter, Open-label, Matched Historical Control Study of Intrathecal SHP611 in Subjects with Late Infantile Metachromatic Leukodystrophy | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004689-32 | A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects with Fabry Disease | 2022-12-16 | bad-data |
| Trial is outside EEC, and reported results | 2020-000226-26 | A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in the ... | bad-data | |
| Ongoing, reported early | 2020-002726-84 | Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-005791-35 | A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on Par... | bad-data | |
| Trial is outside EEC, and reported results | 2021-005404-36 | A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects with Short Bowel Syndrome Who Completed SHP633-302 | bad-data | |
| Trial is outside EEC, and reported results | 2022-002191-36 | A Phase 1, Open-label, Randomized, Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Su... | bad-data |